Intradigm Corporation
Records under this name other than patents Intradigm Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Intradigm Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,691,781 | Compositions for treating respiratory viral infections and their use Term ended Term ended Nov 1, 2025 · From the USPTO record | Term ended | Term ended Nov 1, 2025 | From the USPTO record |
| US 7,893,243 | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases Lapsed on the fee record Ended Feb 22, 2015 · From the USPTO record | Lapsed on the fee record | Ended Feb 22, 2015 | From the USPTO record |
| US 7,893,244 | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases Lapsed on the fee record Ended Feb 22, 2015 · From the USPTO record | Lapsed on the fee record | Ended Feb 22, 2015 | From the USPTO record |
| US 7,786,092 | Composition and method of RNAi therapeutics for treatment of cancer and other neovascularization diseases Lapsed on the fee record Ended Aug 31, 2014 · From the USPTO record | Lapsed on the fee record | Ended Aug 31, 2014 | From the USPTO record |
| US 7,781,414 | Targets for tumor growth inhibition Lapsed on the fee record Ended Aug 24, 2014 · From the USPTO record | Lapsed on the fee record | Ended Aug 24, 2014 | From the USPTO record |
| US 7,723,316 | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases Lapsed on the fee record Ended May 25, 2014 · From the USPTO record | Lapsed on the fee record | Ended May 25, 2014 | From the USPTO record |
| US 7,534,878 | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases Lapsed on the fee record Ended May 19, 2013 · From the USPTO record | Lapsed on the fee record | Ended May 19, 2013 | From the USPTO record |